DJIA 17,031.14 43.63 0.26%
NASDAQ 4,518.90 -48.70 -1.07%
S&P 500 1,984.13 -1.41 -0.07%
market minute promo

MannKind Corp (NASDAQ: MNKD)



company name or ticker

New Diabetes Drugs Gain Approval - Florins Versus Oral Insulin

MannKind In Turmoil: Is It Time To Buy Or Sell?

MannKind: Nothing But Good News, Trading Volume Drops, Short Interest Remains Sky High

Could A MannKind Short Squeeze Be On Its Way?

MannKind Breaks Below 200-Day Moving Average - Notable for MNKD

MannKind's Management Presents at Morgan Stanley Global Healthcare Conference (Transcript)

3 Reasons MannKind Corporation's Stock Could Fall

MannKind is dependent on the launch of inhaled insulin Afrezza and its marketing partner Sanofi.

Why MannKind Corporation Stock Skyrocketed 38% in 2014

MannKind's stock has handily outperformed the S&P 500 in 2014. Find out what's sent its shares higher and whether or not it has more room to run.

Rising Short Interest in Biotech Stocks

Benzinga's Top Initiations

See More Articles...